AegirBio AB (publ) (AEGIR.ST) Research

AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.

Market snapshot

Symbol
AEGIR.ST
Price
$0.43
Day change
+3.88%
Market cap
$158.8K
P/E ratio
-0.00x
52-week range
0.39-1.8
Sector
Healthcare
Industry
Medical - Instruments & Supplies

Peer companies

  • Amniotics AB (publ) (AMNI.ST)
  • Bioservo Technologies AB (publ) (BIOS.ST)
  • Cyxone AB (publ) (CYXO.ST)
  • Diagonal Bio AB (publ) (DIABIO.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • Learning 2 Sleep L2S AB (publ) (L2S.ST)
  • Pharmiva AB (publ) (PHARM.ST)
  • Pharmacolog i Uppsala AB (publ) (PHLOG-B.ST)

Open AegirBio AB (publ) (AEGIR.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.